PD-L1 Antikörper (AA 19-238)
Kurzübersicht für PD-L1 Antikörper (AA 19-238) (ABIN7164674)
Target
Alle PD-L1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 19-238
-
Kreuzreaktivität
- Human
-
Aufreinigung
- Protein G purified
-
Immunogen
- Recombinant Human Programmed cell death 1 ligand 1 protein (19-238AA)
-
Isotyp
- IgG2b
-
-
-
-
Applikationshinweise
- Recommended dilution: WB:1:1000-1:5000, IHC:1:50-1:200, IF:1:50-1:200, FC:1:100-1:300,
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 -
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C,-80 °C
-
Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- PD-L1 (CD274 (PD-L1))
-
Andere Bezeichnung
- PD-L1
-
Hintergrund
-
Background: Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077)
Aliases: Programmed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligand 1) (B7 homolog 1) (B7-H1) (CD antigen CD274), CD274, B7H1 PDCD1L1 PDCD1LG1 PDL1
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-